| Study | Patients | Therapy (dose) | Hypothyroid events of any grade (%) | Hypothyroid events of grade 3–5 | Median follow-up (range) |
|---|
| Westin [1] | 29 | Pidilizumab (3 mg/kg) | 0 (0) | 0 | 15.4 months |
| Weber [2] | 452 | Nivolumab (3 mg/kg) | 49 (10.8) | 1 | 19.5 months/13 monthsa |
| Bellmunt [3] | 266 | Pembrolizumab | 17 (6.4)b | 0 | 14.1 months |
| Herbst [4] | 339 | Pembrolizumab (2 mg/kg) | 28 (8.3) | 0 | 13.1 months (8.6–17–7) |
- aAdverse events were reported up to 30 days after last treatment and treatment duration was up to 12 months at a maximum, for that reason follow-up time regarding adverse events can add up to no more than 13 months
- b10 patients (3.8%) experienced hyperthyroidism
